

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

NUGENE INTERNATIONAL, INC.

701 S. CARSON STREET, SUITE 200
Carson City, NV 89701

1 912-499-1780
emergentcompliance@gmail.com
SIC 2844

Annual Report
For the Period Ending:
December 31, 2021 (the
"Reporting Period")

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

765,895,614

As of September 30, 2021, the number of shares outstanding of our Common Stock was:

764,596,325

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

59,254,155

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☒ No: ☐

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

NuGene International, Inc.
Formerly=Bling Marketing, Inc. until 2-2015

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada October 30, 2013 - Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

701 S. CARSON STREET, SUITE 200
Carson City, NV 89701

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☒ No: ☐

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

Custodianship was granted to Emergent LLC by the Nevada courts.

2) Security Information

Trading symbol:	<u>NUGN</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>67052F102</u>
Par or stated value:	<u>.0001</u>

Total shares authorized: 800,000,000 as of date: December 31, 2021

Total shares outstanding: 765,895,614 as of date: Dec 31, 2021
Number of shares in the Public Float²: as of date: Dec 31, 2021
Total number of shareholders of record: 63 as of date: Dec 31, 2021

All additional class(es) of publicly traded securities (if any):

Trading symbol:
Exact title and class of securities outstanding: Convertible Preferred
CUSIP:
Par or stated value:
Total shares authorized: 24,000,000 as of date: December 31, 2021
Total shares outstanding: 100 as of date: December 31, 2021

Transfer Agent

Name: Olde Monmouth Stock Transfer Co., Inc
Phone: (732) 872-2727
Email: matt@oldemonmouth.com
Address: 200 Memorial Pkwy, Atlantic Heights, NJ 07716

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>01.01.18</u> Common: <u>59,254,155</u> Preferred: <u>1,917,720</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance,	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per	Were the shares issued at a discount	Individual/ Entity Shares were issued to (entities must	Reason for share issuance (e.g. for cash or debt conversion)	Restricted or Unrestricted	Exemption or

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

	cancellation , shares returned to treasury)			share) at Issuance	to market price at the time of issuance? (Yes/No)	have individual with voting / investment control disclosed).	-OR- Nature of Services Provided	as of this filing.	Registration Type.
<u>4.5.2021</u>	<u>New</u>	<u>700,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4.20.21</u>	<u>Cancelled</u>	<u>-2,328,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>4.20.21</u>	<u>New</u>	<u>2,328,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>MICHAEL KOPSTICK</u>	<u>Purchase</u>	<u>Restricted</u>	<u>144</u>
<u>5.07.21</u>	<u>Cancelled</u>	<u>-10,500,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>5.07.21</u>	<u>New</u>	<u>10,500,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>MICHAEL KOPSTICK</u>	<u>Purchase</u>	<u>Restricted</u>	<u>144</u>
<u>6.09.21</u>	<u>Cancelled</u>	<u>-2,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>6.09.21</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>JAMES COWLAND</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>6.17.21</u>	<u>Cancelled</u>	<u>-2,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>6.17.21</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>PAUL SEGURA JR</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>07.02.21</u>	<u>Cancelled</u>	<u>-20,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>07.02.21</u>	<u>New</u>	<u>20,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>FRANK J. HARITON</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>07.08.21</u>	<u>Cancelled</u>	<u>-37,800,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>07.08.21</u>	<u>New</u>	<u>37,800,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>JUDAH AARON STERNHILL</u>	<u>Purchase</u>	<u>Restricted</u>	<u>144</u>
<u>07.21.21</u>	<u>Cancelled</u>	<u>-10,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>07.23.21</u>	<u>New</u>	<u>4,000,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>Milan Hoffman</u>	<u>Conversion from Preferred to Common</u>	<u>Restricted</u>	<u>144</u>
<u>07.23.21</u>	<u>New</u>	<u>958,860</u>	<u>Common</u>	.0001	<u>No</u>	<u>ALI KHARAZMI</u>	<u>Conversion from Preferred to Common</u>	<u>Restricted</u>	<u>144</u>
<u>07.23.21</u>	<u>New</u>	<u>958,860</u>	<u>Common</u>	.0001	<u>No</u>	<u>SAEED KHARAZMI</u>	<u>Conversion from Preferred to Common</u>	<u>Restricted</u>	<u>144</u>
<u>8.17.21</u>	<u>New</u>	<u>800,000</u>	<u>Common</u>	.0001	<u>No</u>	<u>SANDY MILES</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>8.17.21</u>	<u>New</u>	<u>8000</u>	<u>Preferred</u>	.0001	<u>No</u>	<u>Sandy Miles</u>	<u>Services</u>	<u>Restricted</u>	<u>144</u>
<u>9.03.21</u>	<u>New</u>	<u>6,399,416</u>	<u>Common</u>	.0001	<u>No</u>	<u>Eagle Equities LLC Yanky Borenstein</u>	<u>Loan Conversion</u>	<u>Unrestricted</u>	<u>---</u>

9.10.21	Cancelled	-150,000	Common	.0001	No	EMA Financial LLC John Scholz	Loan Conversion	Unrestricted	—
9.13.21	New	2,375,034	Common	.0001	No	EMA Financial LLC John Scholz	Loan Conversion	Unrestricted	—
10.05.21	New	20,000	Preferred	.0001	No	James Cowland	Services	Restricted	144
10.18.21	New	333,333	Common	.0001	No	Sharni Brodesky	Purchase	Restricted	144
10.19.21	New	333,333	Common	.0001	No	Dayna R. Shereck	Purchase	Restricted	144
11.17.21	Cancellation	-10,689,406	Common	.0001	No	Milan Hoffman	Cancellation	Restricted	144
11.17.21	New	10,689,406	Common	.035	No	Eagle Equities LLC Yanky Borenstien	Loan Settlement	Unrestricted	
11.18.21	Cancellation	-20,000,000	Common	.0001	No	Milan Hoffman	Cancellation	Restricted	144
11.18.21	New	5,428,572	Common	.035	No	Power Up Lending Group Ltd. Curt Kramer	Loan Settlement	Unrestricted	
11.30.21	New	8,285,583	Common	.0335	No	EMA Financial Felicia Preston LLC	Loan Settlement	Unrestricted	
12.02.21	New	4,583,333	Common	.035	No	Labrys Fund LP TJ Silverman	Loan Settlement	Unrestricted	
12.06.21	New	6,160,000	Common	.0125	No	SBI Investments LLC Jonathan Juchno	Loan Settlement	Unrestricted	
12.06.21	New	3,960,000	Common	.0001	No	Power Up Lending Group Ltd. Curt Kramer	Loan Settlement	Restricted	144
12.07.21	Cancellation	-30,000,000	Common	.0001	No	Milan Hoffman	Cancellation	Restricted	144
12.13.21	New	19,415,135	Common	.02	No	Auctus Fund LLC Lou Posner	Loan Settlement	Unrestricted	
12.17.21	Cancellation	-8000	Preferred	.10	No	Sandy Miles	Cancellation	Restricted	144
12.17.21	New	800,000	Common	.001	No	Sandy Miles	Purchase	Restricted	144
12.17.21	Cancellation	20,000	Preferred	.001	No	James Cowland	Cancellation	Restricted	144
12.17.21	New	2,000,000	Common	.0001	No	James Cowland	Services	Restricted	144
12.27.21	New	15,898,682	Common	.035	No	Tiger Trout Capital Puerto Rico LLC Alan Masley	Loan Settlement	Unrestricted	

Shares Outstanding on Date of This Report:	
<u>Ending Balance</u>	
<u>Ending Balance:</u>	
Date <u>12.31.21</u>	Common: <u>763,095,614</u>
	Preferred: <u>100</u>

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

*Shares of Series A Preferred stock were converted to common stock and the original designation for Series A Preferred stock was eliminated.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Principal Amount at Issuance (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
Oct 28, 2016	\$120,000	April 28, 2017	Variable conversion price equal to 60% multiplied by the lowest trading price of the previous 30 days.	Ryan C Hodson & Colin Manners Kodiak Capital Group LLC	Loan
Oct, 28 2016	\$120,000	Oct 28, 2017	Variable conversion price equal to 60% multiplied by the lowest trading price of the previous 30 days.	Adam Long Old Main Capital LLC	Loan

*\$1,862,139.61 of preciously held debt has been closed since the last report.

Use the space below to provide any additional details, including footnotes to the table above

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Milan Hoffman
Title: Custodian
Relationship to Issuer: Self

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

No Operations

- B. Please list any subsidiaries, parents, or affiliated companies.

None

- C. Describe the issuers' principal products or services.

None at this time

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

None at this time

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Frank J. Hariton</u>	<u>Secretary</u>	<u>White Plains, NY</u>	<u>20,000,000</u>	<u>Common</u>	<u>2.64%</u>	<u>Rule 144</u>
<u>Milan I. Hoffman</u>	<u>President/Director</u>	<u>Reno, NV</u>	<u>558,682,594*</u>	<u>Common</u>	<u>73.212%</u>	<u>Rule 144</u>
<u>Milan I. Hoffman</u>	<u>President/Director</u>	<u>Reno, NV</u>	<u>100</u>	<u>Preferred A</u>	<u>51%</u>	<u>Voting shares</u>
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

*700,000,000 shares were issued on April 5, 2021 of which 74,421,511 were used to close \$1,862,139.61 of convertible debt. Any undistributed shares will be used to negotiate a suitable merger.

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Frank J. Hariton
Firm: _____
Address 1: 1065 Dobbs Ferry Road,
Address 2: White Plains, NY, 10607, USA
Phone: (914) 674 - 4373
Email: hariton@sprynet.com

Accountant or Auditor

Name: TBD
Firm: _____
Address 1: _____

Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

NuGene International, Inc.
Balance Sheet Prev Year Comparison
As of December 31, 2021

Accrual Basis

	Dec 31, 21	Dec 31, 20	\$ Change	% Change
ASSETS				
Current Assets				
Checking/Savings				
Cash	0.00	0.00	0.00	0.0%
Total Checking/Savings	0.00	0.00	0.00	0.0%
Accounts Receivable	0.00	0.00	0.00	0.0%
Other Current Assets				
Accounts Receivable	0.00	0.00	0.00	0.0%
Inventories	0.00	0.00	0.00	0.0%
Total Other Current Assets	0.00	0.00	0.00	0.0%
Total Current Assets	0.00	0.00	0.00	0.0%
Fixed Assets				
Accumulated Depreciation	0.00	0.00	0.00	0.0%
Furniture and Equipment	0.00	0.00	0.00	0.0%
Property & Equipment	0.00	0.00	0.00	0.0%
Total Fixed Assets	0.00	0.00	0.00	0.0%
Other Assets				
Deposits	0.00	0.00	0.00	0.0%
Security Deposits Asset	0.00	0.00	0.00	0.0%
Total Other Assets	0.00	0.00	0.00	0.0%
TOTAL ASSETS	0.00	0.00	0.00	0.0%
LIABILITIES & EQUITY				
Liabilities				
Current Liabilities				
Accounts Payable	0.00	0.00	0.00	0.0%
Credit Cards	0.00	0.00	0.00	0.0%
Other Current Liabilities				
Accounts Payable	0.00	0.00	0.00	0.0%
Derivative Liabilities	0.00	0.00	0.00	0.0%
Notes Payable	0.00	0.00	0.00	0.0%
Payroll Liabilities	0.00	0.00	0.00	0.0%
Related Parties Payable	0.00	0.00	0.00	0.0%
Total Other Current Liabil...	0.00	0.00	0.00	0.0%
Total Current Liabilities	0.00	0.00	0.00	0.0%
Long Term Liabilities	0.00	0.00	0.00	0.0%
Total Liabilities	0.00	0.00	0.00	0.0%
Equity				
Additional Paid in Capital	12,641,673.00	12,641,673.00	0.00	0.0%
Capital Stock	0.00	0.00	0.00	0.0%
Common Stock	76,309.00	5,925.00	70,000.00	1,187.9%
Dividends Paid	0.00	0.00	0.00	0.0%
Opening Balance Equity	0.00	0.00	0.00	0.0%
Preferred Stock	0.00	192.00	0.00	0.0%
Retained Earnings	-12,717,982.00	-12,647,598.00	0.00	0.0%
Net Income	-70,000.00	0.00	-70,000.00	-100.0%
Total Equity	0.00	0.00	0.00	0.0%
TOTAL LIABILITIES & EQUITY	0.00	0.00	0.00	0.0%

NuGene International, Inc.
Profit & Loss Prev Year Comparison
Oct through Dec 2021

Accrual Basis

	<u>Oct – Dec 21</u>	<u>Oct - Dec 20</u>	<u>\$ Change</u>	<u>% Change</u>
Ordinary Income/Expense				
Income				
Merchandise Sales	0.00	0.00	0.00	0.0%
Sales Discounts	0.00	0.00	0.00	0.0%
Total Income	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Cost of Goods Sold				
Merchant Account Fees	0.00	0.00	0.00	0.0%
Total COGS	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Gross Profit	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Expense				
Advertising and Promotion	0.00	0.00	0.00	0.0%
Automobile Expense	0.00	0.00	0.00	0.0%
Bank Service Charges	0.00	0.00	0.00	0.0%
Computer and Internet Expen...	0.00	0.00	0.00	0.0%
Depreciation Expense	0.00	0.00	0.00	0.0%
Insurance Expense	0.00	0.00	0.00	0.0%
Interest Expense	0.00	0.00	0.00	0.0%
Janitorial Expense	0.00	0.00	0.00	0.0%
Meals and Entertainment	0.00	0.00	0.00	0.0%
Office Supplies	0.00	0.00	0.00	0.0%
Payroll Expenses	0.00	0.00	0.00	0.0%
Professional Fees	0.00	0.00	0.00	0.0%
Rent Expense	0.00	0.00	0.00	0.0%
Repairs and Maintenance	0.00	0.00	0.00	0.0%
Telephone Expense	0.00	0.00	0.00	0.0%
Uniforms	0.00	0.00	0.00	0.0%
Utilities	0.00	0.00	0.00	0.0%
Total Expense	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Net Ordinary Income	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Other Income/Expense				
Other Income	0.00	0.00	0.00	0.0%
Other Expense	0.00	0.00	0.00	0.0%
Total Other Expense	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Net Other Income	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Net Income	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>

NuGene International, Inc.
Statement of Cash Flows
Oct through Dec 2021

	<u>Oct - Dec 21</u>
OPERATING ACTIVITIES	
Net Income	0.00
Adjustments to reconcile Net Income to net cash provided by operations:	
Accounts Receivable	0.00
Inventories	0.00
Accounts Payable	0.00
Derivative Liabilities	0.00
Notes Payable	0.00
Payroll Liabilities	0.00
Related Parties Payable	0.00
Net cash provided by Operating Activities	<u>0.00</u>
INVESTING ACTIVITIES	
Accumulated Depreciation	0.00
Furniture and Equipment	0.00
Property & Equipment	0.00
Deposits	0.00
Security Deposits Asset	0.00
Net cash provided by Investing Activities	<u>0.00</u>
FINANCING ACTIVITIES	
Additional Paid in Capital	0.00
Capital Stock	0.00
Common Stock	0.00
Dividends Paid	0.00
Opening Balance Equity	0.00
Preferred Stock	0.00
Retained Earnings	0.00
Net cash provided by Financing Activities	<u>0.00</u>
Net cash increase for period	0.00
Cash at beginning of period	<u>0.00</u>
Cash at end of period	<u><u>0.00</u></u>

NUGENE INTERNATIONAL, INC.
Statements of Shareholders' Equity (Deficit)

	Preferred Stock Shares	Amount	Common Stock Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at DECEMBER 31, 2017	1,917,720	192	59,254,155	\$ 5,925	\$ 12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at DECEMBER 31, 2018	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at March 31, 2019	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at June 30, 2019	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at September 30, 2019	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at DECEMBER 31, 2019	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at March 31, 2020	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at June 30, 2020	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	\$0
Net Loss						-	
Balance at September 30, 2020	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	0
Net Loss						-	
Balance at DECEMBER 31, 2020	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	0
Net Loss						-	
Balance at MARCH 31, 2021	1,917,720	192	59,254,155	5,925	12,641,673	(12,647,790)	0
Net Loss			700,000,000	70,000		(70,000)	
Balance at June 30, 2021	1,917,720	192	759,254,155	75,925	12,641,673	(12,717,790)	0
Net Loss			5,342,170	5,342			
Balance at September 30, 2021	8000	0	764,596,325	76,596	12,641,673	(12,718,269)	0
Net Loss						-	
Balance at December 31, 2021	100	0	765,895,614	76,309	12,641,673	(12,717,790)	0

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Milan Hoffman certify that:

1. I have reviewed this Quarterly Disclosure Statements of NUGENE INTERNATIONAL, INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 27, 2021 [Date]

/s/Milan Hoffman [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Milan Hoffman certify that:

1. I have reviewed this Quarterly Disclosure Statements of NUGENE INTERNATIONAL, INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 27, 2021 [Date]

/s/Milan Hoffman [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

NUGENE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For The
Period Ended December 31, 2021

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The Company

NuGene International, Inc. is a Nevada entity, founded in 2013, previously specializing in the development and marketing of a diverse line of proprietary stem cell based products. The entity currently has no operations.

Basis of presentation

The unaudited consolidated financial statements of the Company have been prepared in accordance with the U.S. Generally Accepted Accounting Principles ("U.S. GAAP").

NOTE 2: STOCKHOLDERS EQUITY

As of December 31, 2021, and December 31, 2020, the Issuer's outstanding and authorized common shares and shareholders were approximately as follows:

- (i) December 31, 2021
- (ii) 800,000,000 shares of common stock authorized
- (iii) 765,895,614 shares of common stock outstanding
- (iv) 103,340,973 common shares were free trading;
- (v) 63 shareholders of record
- (i) December 31, 2020
- (ii) 100,000,000 shares of common stock authorized
- (iii) 59,254,155 shares of common stock outstanding
- (iv) 39,669,494 common shares were free trading;
- (v) 58 shareholders of record

Item 4 Management's Discussion and Analysis or Plan of Operation.

Management's Discussion and Analysis of Financial Condition and Results of Operations, which we refer to as MD&A, is intended to help the reader understand NuGene International, Inc., our operations and our present business environment. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes for the period ended December 31, 2021.

Business Overview

NuGene International, Inc. currently has no operations.

Item 5 Legal Proceedings.

None

Item 6 Defaults on Senior Securities.

None.

Item 7 Other Information.

None.

Item 8 Subsequent Events

700,000,000 shares were issued on April 5, 2021 of which 74,421,511 were used to close \$1,862,139.61 of convertible debt. Any undistributed shares will be used to negotiate a merger.